NYMOX PHARMACEUTICAL CORPORATION
NASDAQ : NYMX

NYMOX PHARMACEUTICAL CORPORATION

February 24, 2005 11:15 ET

Studies Show that Nymox NXC-4720 Product Can Substantially Reduce E. Coli Meat Contamination


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: NYMOX PHARMACEUTICAL

NASDAQ SYMBOL: NYMX

FEBRUARY 24, 2005 - 11:15 ET

Studies Show that Nymox NXC-4720 Product Can
Substantially Reduce E. Coli Meat Contamination

MAYWOOD, N.J.--(CCNMatthews - Feb 24, 2005) -

Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) announced today that
its proprietary NXC-4720 product for the treatment of potentially fatal
E. coli O157:H7 contamination is capable of reducing the level of
contamination on fresh beef by 99% according to laboratory studies. The
studies used fresh beef samples inoculated with E. coli O157:H7 bacteria
and then treated with the Company's product. Nymox's NXC-4720 product is
designed for the treatment of meat at the processing stage.

E. coli O157:H7 bacterial contamination is a major public health problem
throughout the world. This type of E. coli infection can cause severe
bloody diarrhea and abdominal cramps and can lead to kidney failure,
particularly in young children and in the elderly, with often serious
long term and sometimes fatal results. E. coli O157 contamination is a
serious problem for the meat packing industry. One United States
Department of Agriculture (USDA) study estimated the direct and indirect
costs of foodborne E. coli O157 infections at over $650 million per
year. In 2002 alone, over 23 million pounds of meat were recalled in the
U.S. because of possible E. coli contamination, affecting all sectors of
the meat industry from large meat processors to local supermarkets and
many consumers. On average, Americans consume over 65 pounds of beef per
person per year.

The Company earlier announced an agreement with the Public Health Agency
of Canada for the treatment of E. coli O157 infection in cattle. The
agreement is part of a collaboration between the Company and Dr. Roger
Johnson and the Laboratory for Foodborne Zoonoses. Reducing or
eliminating E. coli O157:H7 in cattle has potential benefits not only
for the safety of beef products but also for public water supplies that
can become contaminated from run-off from cattle farming operations
where there are cattle harboring the deadly bacteria.

Nymox Pharmaceutical Corporation is a biotechnology company engaged in
the research and development of therapeutics and diagnostics, with a
particular emphasis on products targeted for the unmet needs of the
aging population. Currently Nymox has three products on the market, and
a healthy pipeline of drug and diagnostic products. The Company also has
several hundred patents and patent applications. Nymox developed
AlzheimAlert™, a test to aid in the diagnosis of Alzheimer's disease.
The AlzheimAlert™ test has CLIA approval in the U.S. and recently
received the CE Mark making it eligible for sale in European countries.
The Company has successfully completed two U.S. Phase 1 and Phase 1-2
clinical trials for NX-1207, its drug for benign prostatic hyperplasia
(BPH). The Company markets NicAlert™ and TobacAlert™ tests for
measuring tobacco product exposure. Nymox has a number of drugs in
development for Alzheimer's disease, oncology, and infectious disease.

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of
1995 that involve a number of risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and the actual
results and future events could differ materially from management's
current expectations. The conduct of clinical trials and the development
of drug products involve substantial risks and uncertainties and actual
results may differ materially from expectations. Promising early results
do not ensure that later stage or larger scale clinical trials will be
successful or will proceed as expected. Such factors are detailed from
time to time in Nymox's filings with the United States Securities and
Exchange Commission and other regulatory authorities.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    website: http://www.nymox.com